{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:10:45Z","timestamp":1787656245693,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Regorafenib is a multikinase inhibitor widely used in oncology, but it is associated with significant adverse events (AEs), particularly hepatotoxicity. Understanding the real-world safety profile and the molecular mechanisms underlying regorafenib-induced liver failure is critical for clinical risk management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AE reports with regorafenib as the primary suspect drug were extracted from the FDA Adverse Event Reporting System (FAERS) from Q3 2012 to Q1 2025. Disproportionality analyses were conducted using reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN). Clinical prioritization was assessed via a semi-quantitative framework. Time-to-onset was analyzed using Weibull distribution. Additionally, network toxicology and molecular docking were employed to explore potential mechanisms and binding affinities between regorafenib and liver failure targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 9,442 AE reports were analyzed. Hepatobiliary disorders exhibited the strongest signal strength (ROR = 2.66, 95% CI: 2.50\u20132.83), with hepatic failure and fulminant hepatitis identified as high-priority AEs. The majority of AEs occurred within 30 days of treatment initiation. Subgroup analysis indicated that elderly patients (\u226565 years) and males had higher risks of liver failure, whereas higher body weight appeared protective. Network analysis identified 63 overlapping targets, with MAPK and PI3K-Akt signaling pathways significantly enriched.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pharmacovigilance analysis identifies regorafenib-associated hepatotoxicity as a significant safety signal, with higher risks observed in elderly and male patients. Computational predictions suggest the involvement of MAPK and PI3K-Akt pathways, offering a theoretical basis for further mechanistic investigation and supporting the need for vigilant clinical monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1698511","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:57:51Z","timestamp":1768204671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world safety profile and mechanistic insights into regorafenib-induced liver failure: a pharmacovigilance study integrated with network toxicology"],"prefix":"10.3389","volume":"16","author":[{"given":"Haonan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengkai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","first-page":"4037","article-title":"Acute liver failure due to regorafenib may be caused by impaired liver blood flow: a case report","volume":"35","author":"Akamine","year":"2015","journal-title":"Anticancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","article-title":"Lenvatinib: a review in hepatocellular carcinoma","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the u.s. Food and drug administration adverse event reporting system (faers)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"585480547","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2428828","DOI":"10.1001\/jamanetworkopen.2024.28828","article-title":"Incidence and survival outcomes of gastrointestinal stromal tumors","volume":"7","author":"Alvarez","year":"2024","journal-title":"Jama Netw. Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/archdermatol.2011.719","article-title":"Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents","volume":"147","author":"Borovicka","year":"2011","journal-title":"Arch. Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the fda adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2023.2219892","article-title":"An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting","volume":"22","author":"Crisafulli","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11864-025-01304-w","article-title":"Recent advances in succinate dehydrogenase deficient gastrointestinal stromal tumor systemic therapies","volume":"26","author":"Dedousis","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: reachin, a randomized, double-blind, phase ii trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for hcc: additional analyses from the phase iii resorce trial","volume":"69","author":"Finn","year":"2018","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","article-title":"Liver diseases: epidemiology, causes, trends and predictions","volume":"10","author":"Gan","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: Asco guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (correct): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12885-025-13722-y","article-title":"Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis","volume":"25","author":"Han","year":"2025","journal-title":"Bmc Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"106055","DOI":"10.1016\/j.phrs.2021.106055","article-title":"Polypharmacology: the science of multi-targeting molecules","volume":"176","author":"Kabir","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1111\/bcp.14334","article-title":"Population pharmacokinetics of regorafenib in solid tumours: exposure in clinical practice considering enterohepatic circulation and food intake","volume":"86","author":"Keunecke","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3892\/ol.2015.3853","article-title":"Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: a case report","volume":"11","author":"Kuwayama","year":"2016","journal-title":"Oncol. Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"110763","DOI":"10.1016\/j.cbi.2023.110763","article-title":"Pectolinarigenin attenuates hepatic ischemia\/reperfusion injury via activation of the pi3k\/akt\/nrf2 signaling pathway","volume":"386","author":"Li","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1027112","DOI":"10.3389\/fphar.2022.1027112","article-title":"Exploring the mechanism of alisma orientale for the treatment of pregnancy induced hypertension and potential hepato-nephrotoxicity by using network pharmacology, network toxicology, molecular docking and molecular dynamics simulation","volume":"13","author":"Liao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41575-023-00841-9","article-title":"Changing epidemiology of colorectal cancer - birth cohort effects and emerging risk factors","volume":"21","author":"Murphy","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.livres.2024.11.006","article-title":"Kehuang capsule inhibits mapk and akt signaling pathways to mitigate ccl(4)-induced acute liver injury","volume":"8","author":"Ni","year":"2024","journal-title":"Liver Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-biochem-030222-120000","article-title":"The art and science of molecular docking","volume":"93","author":"Paggi","year":"2024","journal-title":"Annu. Rev. Biochem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J. Am. Acad. Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the fda adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"889088","DOI":"10.3389\/fphar.2022.889088","article-title":"Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data","volume":"13","author":"Sauzet","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1389329","DOI":"10.3389\/fmed.2024.1389329","article-title":"The role of pi3k\/akt signaling pathway in attenuating liver fibrosis: a comprehensive review","volume":"11","author":"Shamsan","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"David: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The string database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.21037\/jgo.2015.11.01","article-title":"Regorafenib could cause sinusoidal obstruction syndrome","volume":"7","author":"Takahashi","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1124\/mol.110.065839","article-title":"Mechanism-based inactivation of cytochrome p450 3a4 by lapatinib","volume":"78","author":"Teng","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","article-title":"Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab","volume":"10","author":"Toulmonde","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/pharmaceutics13030386","article-title":"Effect of synchronous versus sequential regimens on the pharmacokinetics and biodistribution of regorafenib with irradiation","volume":"13","author":"Tsai","year":"2021","journal-title":"Pharmaceutics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e70065","DOI":"10.1002\/cam4.70065","article-title":"Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: a retrospective study","volume":"13","author":"Uekusa","year":"2024","journal-title":"Cancer Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"110516","DOI":"10.1016\/j.intimp.2023.110516","article-title":"Integrating network pharmacology and pharmacological evaluation to reveal the therapeutic effects and potential mechanism of s-allylmercapto-n-acetylcysteine on acute respiratory distress syndrome","volume":"121","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1129730","DOI":"10.3389\/fphar.2023.1129730","article-title":"Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: a systematic literature review of published case reports and disproportionality analysis based on the faers database","volume":"14","author":"Xia","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2205483","DOI":"10.1002\/advs.202205483","article-title":"Targeting the lysosomal degradation of rab22a-neof1 fusion protein for osteosarcoma lung metastasis","volume":"10","author":"Zeng","year":"2023","journal-title":"Adv. Sci. (Weinh)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1698511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:57:53Z","timestamp":1768204673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1698511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1698511"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1698511","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1698511"}}